Ad-hoc | 18 April 2002 07:55

Stratec Biomedical Sys. english

Stratec and Bayer Diagnostics announce conclusion of contract Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– According to § 15 WpHG, the Board of Management of STRATEC Biomedical Systems AG announces the successful conclusion of a long term contract. The contract concluded between Stratec and Bayer Corporation, through its Business Group Diagnostics, covers the development of a new analyzer by Stratec for Bayer. Following the successful completion of the development – intended for 2004 – and the fulfillment of the contract by both parties, the parties have agreed on a subsequent supply contract covering the purchase of a minimum quantity of analyzer systems by Bayer for a period of several years. For competitive reasons the two companies agreed to maintain silence regarding the contract volume and technology. STRATEC Biomedical Systems AG is currently working on several major projects which will reach the phase of clinical testing and market launch in the periods to come. end of ad-hoc-announcement (c)DGAP 18.04.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: About Bayer Diagnostics With approximately 7,000 employees worldwide and 2001 sales of $1.8 billion (Mrd.), Bayer Diagnostics (www.bayerdiag.com), based in Tarrytown, New York, U.S.A., is one of the largest diagnostic businesses in the world. The organization supports customers in 100 countries through an extensive portfolio of central, self-testing, nucleic acid and near patient care diagnostics systems and services for use in the assessment and management of health, including the areas of cardiovascular and kidney disease, oncology, virology, women’s health and diabetes. Bayer Diagnostics is a part of the worldwide Bayer Group, a $29 billion (Mrd.) international health care and chemicals group based in Leverkusen, Germany. Bayer Diagnostics’ global headquarters in the United States operates as part of Bayer Corporation of Pittsburgh, a research-based company with major businesses in health care, life sciences and chemicals. About Stratec Based on its own patent-protected technologies STRATEC Biomedical Systems AG (SIN 728900 and 724 158 www.stratec-biomedical.de) designs and manufactures fully automated systems for partners in clinical diagnostics and biotechnology. These partners sell the analyzers to laboratories and research institutes worldwide as system solutions together with their reagents. Following its business model, STRATEC Biomedical Systems AG maintains ongoing negotiations with major diagnostics and life-science companies. The successful conclusion of contracts and completion of the design processes could lead to further significant growth of the company. For further information, please contact us at +49 (0)7082 – 791633 or ir@stratec-biomedical.de. ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Stuttgart und Frankfurt (SMAX); Freiverkehr in Berlin, Düsseldorf und Hamburg 180755 Apr 02